Identification

Generic Name
Triglu-5-formyl-tetrahydrofolate
DrugBank Accession Number
DB02067
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 731.6673
Monoisotopic: 731.251082315
Chemical Formula
C30H37N9O13
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
USerine hydroxymethyltransferase, cytosolicNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CapecitabineThe risk or severity of adverse effects can be increased when Triglu-5-formyl-tetrahydrofolate is combined with Capecitabine.
CarbamazepineThe serum concentration of Triglu-5-formyl-tetrahydrofolate can be decreased when it is combined with Carbamazepine.
ColestipolThe serum concentration of Triglu-5-formyl-tetrahydrofolate can be decreased when it is combined with Colestipol.
CycloguanilThe therapeutic efficacy of Cycloguanil can be decreased when used in combination with Triglu-5-formyl-tetrahydrofolate.
DapsoneThe therapeutic efficacy of Dapsone can be decreased when used in combination with Triglu-5-formyl-tetrahydrofolate.
FlucytosineThe risk or severity of adverse effects can be increased when Triglu-5-formyl-tetrahydrofolate is combined with Flucytosine.
FluorouracilThe risk or severity of adverse effects can be increased when Triglu-5-formyl-tetrahydrofolate is combined with Fluorouracil.
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Triglu-5-formyl-tetrahydrofolate.
GlucarpidaseThe serum concentration of the active metabolites of Triglu-5-formyl-tetrahydrofolate can be reduced when Triglu-5-formyl-tetrahydrofolate is used in combination with Glucarpidase resulting in a loss in efficacy.
MethotrexateThe therapeutic efficacy of Methotrexate can be decreased when used in combination with Triglu-5-formyl-tetrahydrofolate.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as tetrahydrofolic acids and derivatives. These are heterocyclic compounds based on the 5,6,7,8-tetrahydropteroic acid skeleton conjugated with at least one L-glutamic acid unit (or a derivative thereof) .
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pteridines and derivatives
Sub Class
Pterins and derivatives
Direct Parent
Tetrahydrofolic acids and derivatives
Alternative Parents
Oligopeptides / Gamma-glutamyl amino acids / Glutamic acid and derivatives / Glutamine and derivatives / Tetracarboxylic acids and derivatives / Hippuric acids / N-acyl-L-alpha-amino acids / Aminobenzamides / Phenylalkylamines / Aniline and substituted anilines
show 16 more
Substituents
Alpha-amino acid or derivatives / Alpha-oligopeptide / Amine / Amino acid / Amino acid or derivatives / Aminobenzamide / Aminobenzoic acid or derivatives / Aminopyrimidine / Aniline or substituted anilines / Aromatic heteropolycyclic compound
show 39 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
ZLOMJLIQXBKNHU-VJANTYMQSA-N
InChI
InChI=1S/C30H37N9O13/c31-30-37-24-23(26(46)38-30)39(13-40)16(12-33-24)11-32-15-3-1-14(2-4-15)25(45)36-19(29(51)52)6-9-21(42)34-17(27(47)48)5-8-20(41)35-18(28(49)50)7-10-22(43)44/h1-4,13,16-19,32H,5-12H2,(H,34,42)(H,35,41)(H,36,45)(H,43,44)(H,47,48)(H,49,50)(H,51,52)(H4,31,33,37,38,46)/t16-,17-,18-,19-/m0/s1
IUPAC Name
(2S)-2-[(4S)-4-[(4S)-4-{[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]formamido}-4-carboxybutanamido]-4-carboxybutanamido]pentanedioic acid
SMILES
[H]N([H])C1=NC(=O)C2=C(N([H])C[C@H](CN([H])C3=CC=C(C=C3)C(=O)N([H])[C@@H](CCC(=O)N([H])[C@@H](CCC(=O)N([H])[C@@H](CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)N2C=O)N1[H]

References

General References
Not Available
PubChem Compound
6323515
PubChem Substance
46506661
ChemSpider
4883456
ChEMBL
CHEMBL1236268
ZINC
ZINC000055398661
PDBe Ligand
TGF
PDB Entries
1ls3

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.39 mg/mLALOGPS
logP-1.6ALOGPS
logP-5.8Chemaxon
logS-3.3ALOGPS
pKa (Strongest Acidic)2.34Chemaxon
pKa (Strongest Basic)4.71Chemaxon
Physiological Charge-4Chemaxon
Hydrogen Acceptor Count18Chemaxon
Hydrogen Donor Count11Chemaxon
Polar Surface Area348.35 Å2Chemaxon
Rotatable Bond Count19Chemaxon
Refractivity182.64 m3·mol-1Chemaxon
Polarizability69.92 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.5164
Blood Brain Barrier-0.8298
Caco-2 permeable-0.8857
P-glycoprotein substrateSubstrate0.7182
P-glycoprotein inhibitor INon-inhibitor0.8926
P-glycoprotein inhibitor IINon-inhibitor0.9812
Renal organic cation transporterNon-inhibitor0.8557
CYP450 2C9 substrateNon-substrate0.8044
CYP450 2D6 substrateNon-substrate0.8068
CYP450 3A4 substrateNon-substrate0.5836
CYP450 1A2 substrateNon-inhibitor0.8637
CYP450 2C9 inhibitorNon-inhibitor0.8848
CYP450 2D6 inhibitorNon-inhibitor0.9414
CYP450 2C19 inhibitorNon-inhibitor0.8737
CYP450 3A4 inhibitorNon-inhibitor0.8519
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.915
Ames testNon AMES toxic0.7793
CarcinogenicityNon-carcinogens0.93
BiodegradationNot ready biodegradable0.8919
Rat acute toxicity2.4031 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8978
hERG inhibition (predictor II)Non-inhibitor0.5203
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serine binding
Specific Function
Interconversion of serine and glycine.
Gene Name
SHMT1
Uniprot ID
P34896
Uniprot Name
Serine hydroxymethyltransferase, cytosolic
Molecular Weight
53082.18 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52